High-yield points
- Target: the posteroventral GPi. Bilateral GPi is the standard for childhood dystonia .
- Coordinates: start about 20–22 mm lateral, 2–4 mm anterior to the midcommissural point and 2–4 mm below AC–PC, then refine on MRI. The internal capsule is medial and the optic tract below. Use the pallidocapsular line and the optic tract as the landmarks .
- Asleep, image-verified placement gives sub-millimeter to 1–2 mm accuracy in children .
- Programming: improvement builds over months. Shorter pulse widths save battery and may limit bradykinesia .
- Best candidates: inherited or idiopathic dystonia without brain injury, especially TOR1A, about 70% improvement .
- Less predictable: THAP1 and KMT2B (less sustained), and PKAN (classic about 16%) .
- Dyskinetic cerebral palsy: about 24% motor improvement, but meaningful goal gains are possible. Set expectations carefully .
- Operate earlier: a shorter disease duration predicts a better result .
- Status dystonicus: DBS resolves it in nearly all reported cases, with lower mortality than medical treatment .
- Risk: major complications in about 16% of children treated for movement disorders, with higher risk in small, urgent cases. In the US, the device exemption covers children 7 and older .
Pallidal (GPi) deep brain stimulation is an established treatment for medically refractory dystonia in children. How well it works depends mostly on the cause of the dystonia. Inherited and idiopathic dystonias without structural brain injury respond best; acquired (dyskinetic cerebral palsy) and degenerative dystonias respond less.
Who gets it
- Access in the US: DBS for dystonia is available to children 7 and older through an FDA Humanitarian Device Exemption. Younger children are treated off-label .
- Who is being treated: in a UK-wide study of 139 children and young people with DBS (median age at surgery 9.8 years):
- 49.6% had dyskinetic cerebral palsy, 9.4% KMT2B dystonia and 6.5% TOR1A dystonia.
- The modal GMFCS level was V .
Outcomes by cause
- Overall (individual-patient meta-analysis, 321 children aged 21 or younger):
- 86.3% improved at a median of 12 months, and 66.1% had a clinically significant (more than 20%) motor improvement.
- Better outcome was predicted by older age at onset, inherited dystonia without nervous-system pathology or idiopathic dystonia, and truncal involvement .
- Inherited, non-degenerative dystonia (224 patients in a meta-analysis, mean follow-up 3 years):
- Mean motor improvement was 58.9% at 1 year and 57.2% at last follow-up.
- By gene :
- TOR1A (DYT1): the best and most durable response, 69.6% at 1 year and 67.3% later.
- SGCE: 63% at 1 year.
- THAP1 (DYT6): less sustained, 52.3% at 1 year and 42.0% later.
- KMT2B: 38.0% at 1 year and 26.7% later.
- In a separate multicenter series, DYT6 responded less predictably early (32% vs 60% for DYT1), but the groups converged later .
- KMT2B (DYT28):
- More than half improved by over 30% at 1 year, and the benefit was sustained in 5 of 8 patients beyond 5 years.
- Trunk and cervical dystonia improved most and laryngeal dystonia least. No one regained a fully independent gait, and 5 patients developed mild parkinsonism .
- GNAO1: 37.9% motor improvement, with 80% of patients counted as responders. All reported episodes of status dystonicus resolved, but 18% had skin erosion or infection .
- PKAN (degenerative): motor improvement was 26% at 1 year overall: 45% in atypical cases vs 16% in classic. Disability improved only in atypical cases .
- Dyskinetic cerebral palsy:
- Meta-analysis: motor improvement was 23.6%, with only 9.2% improvement in disability. More severe dystonia predicted a worse response .
- Adult prospective pilot: motor improvement was 24.4% at 1 year in adults with little spasticity and near-normal basal ganglia on MRI .
- Pediatric trial (STIM-CP, 16 children): the quality-of-life primary endpoint was not met. Individual goal performance and physical health improved .
- At 3 years: dyskinesia improved significantly, but other measures did not change, and 12 serious adverse events were possibly related to treatment .
- Goals can improve without much change in the dystonia score: children's self-selected goal performance (COPM) rose from a median of 2.8 to 6.1 by 5 years, with similar caregiver reports, while the median dystonia score fell only from 81 to 70. Functional gains occurred despite limited dystonia reduction, especially in dyskinetic cerebral palsy .
Predictors of a good result
- Cause and anatomy: inherited or idiopathic dystonia without brain pathology predicts a better outcome .
- Shorter disease duration:
- Shorter duration and a smaller proportion of life lived with dystonia predicted better disability outcomes .
- Regardless of genotype, a shorter time from onset to surgery predicted better control, so DBS should be considered earlier in the course .
- Truncal involvement in primary dystonia predicted greater improvement .
- Worse result: secondary dystonia with a high baseline score, truncal involvement and surgery at a younger age .
- Genetic testing before surgery helps set expectations, given the gene-specific differences in response .
Targeting the GPi
- The target is the posteroventral (sensorimotor) GPi:
- Active contacts giving more than 50% improvement sat near the intercommissural plane, a mean 3.7 mm from the pallidocapsular border .
- Probabilistic "sweet spot" studies:
- In 87 adults, benefit mapped to the ventroposterior GPi and the adjacent subpallidal white matter. Outcome tracked the stimulated volume, not the electrode location alone .
- In DYT1 patients, the therapeutic volume was centered in the posterior GP (about 153 mm³) .
- In 52 children, the best-responding volume in genetic or idiopathic dystonia lay in the posterior ventrolateral GPi, slightly posterior and superior to the usual target. No sweet spot emerged in cerebral palsy .
- In pediatric status dystonicus, stimulation of the posterior-ventrolateral GPi was associated with improvement .
- Indirect (AC–PC) starting coordinates: about 20–22 mm lateral to midline, 2–4 mm anterior to the midcommissural point, and 2–4 mm below the AC–PC line .
- Example: a 7-year-old with DYT1 dystonia was implanted 21.5 mm lateral, 2.8 mm anterior and 4 mm below the AC–PC plane .
- Adjust to the patient's own anatomy: atlas-based coordinates differed significantly from targets chosen directly on MRI, so refine the plan on the individual scan .
- Pallidal size matters: patients who improved less had smaller GPi volumes than good responders .
- Direct, landmark-based targeting (Ponce and colleagues):
- The optic tract and the pallidocapsular line are the key landmarks for refining the GPi target, with the GPi best seen on FGATIR imaging .
- In asleep GPi DBS with direct anatomical targeting and intraoperative CT, radial error was 0.8 mm. The mean active contact sat 21.4 mm lateral, 4.7 mm anterior and 0.4 mm superior to the midcommissural point . That series was in Parkinson disease.
- Asleep and awake GPi placement gave equivalent motor outcomes in Parkinson disease (37.5% vs 38.5% improvement) .
- Physiological signposts along the trajectory:
- Bursting and pausing cells in GPe.
- Border cells at the dorsal GPi border.
- Irregular firing within GPi.
- A drop in activity past the ventral GPi border.
- Light-evoked activity in the optic tract below .
- Stay clear of neighboring structures: the internal capsule lies medially and the optic tract below.
- Capsular thresholds can be tested under general anesthesia with microelectrode stimulation .
- Motor evoked potential thresholds tracked distance to the internal capsule .
Surgical technique in children
- Most children can't tolerate awake surgery, so leads are usually placed under general anesthesia .
- Interventional MRI ("asleep," image-verified):
- In 6 children (5 DYT1), lead error was 0.6 mm, and motor improvement was 86–88% at 6–12 months, with no serious adverse events .
- In a mostly adult iMRI series, error was 0.93 mm and improvement 63% at 1 year. Serious complications occurred in 20% early in the program's experience .
- Frame or robot with intraoperative imaging:
- In 24 children, median target error was 1.28 mm with a frameless robot vs 1.69 mm with a frame, with no major complications .
- In another series, a robot reduced error (1.15 vs 2.80 mm) with equivalent clinical results .
- Microelectrode recording (MER):
- MER is possible under sevoflurane anesthesia .
- In dystonia, GPi and GPe neurons fire at similar rates, so tell them apart by discharge pattern, not rate .
Programming
- Expect a slow response: with 60 Hz stimulation from the start, median improvement rose from 38% at 1 month to 89% at 1 year .
- The lack of immediate feedback makes dystonia programming less intuitive than in Parkinson disease .
- Typical settings: in the pediatric iMRI series, mean GPi settings at 12 months were 3.0 V, 83 µs and 135 Hz .
- Pulse width:
- Short (60–90 µs) and long (450 µs) pulse widths gave similar outcomes, but short pulses extended battery life (1,129 vs 925 days) .
- Stimulation-induced bradykinesia affected 60–72% of patients, was predicted by pulse width, and mapped to a posterolateral GPi "sour spot" separate from the sweet spot .
Status dystonicus
- DBS as rescue: status dystonicus resolved with DBS in all 8 children of a multicenter series and in 73 of 74 published cases, mostly within 2–4 weeks .
- GPi was the target in 68 of 77 published cases.
- Mortality in the review was 4%, vs 10–12.5% reported with medical treatment alone .
- Consensus pathways cover recognition, supportive and dystonia-directed treatment, and when to bring in neuromodulation .
Complications
- Complications are higher in movement disorders than epilepsy: in the North American CHILD-DBS registry (130 children), major complications occurred in 11.5% overall but 15.6% of those treated for movement disorders (vs 4.3% for epilepsy).
- Lower weight and urgent surgery were risk factors.
- Infection occurred in 6.2% and hardware malfunction in 3.1% .
- Children under 7 (12 children, mean weight 16.5 kg):
- 64.3% of surgeries were urgent.
- 3 had frame pins penetrate the inner table of the skull, and 4 had wound complications needing surgery. No one had neurological sequelae.
- Motor improvement was 40.1% at 6 months .
- PKAN: infection 6% and hardware failure 7% .
Related topics
- Spasticity vs. Dystonia: telling the two apart before choosing surgery.
- Surgical Management of Spasticity: ITB and SDR for the spastic component.
- MR-Guided Focused Ultrasound: the lesional alternative and pediatric prospects.
- Neurosurgical Delivery of Therapies for Inherited Metabolic and Genetic Brain Disorders: stereotactic, intraventricular and intrathecal delivery of genetic therapies.
- GPi Deep Brain Stimulation: Procedure and Targeting: step-by-step procedure.
References
- Jung S, Molot-Toker S, Dinger TF, et al. Safety, feasibility, and outcomes of deep brain stimulation in young children excluded from the FDA Humanitarian Device Exemption: analysis of the CHILD-DBS registry. J Neurosurg Pediatr 2026;38(4):430–441. doi:10.3171/2026.2.PEDS25517. PMID 42566800. verified
- Lumsden DE, Ramiah R, Smallbone T, et al. Deep brain stimulation in the management of movement disorders in childhood: a UK-wide cross-sectional study. Arch Dis Child 2026;111(2):147–152. doi:10.1136/archdischild-2025-328889. PMID 41093365. verified
- Duga V, Giossi R, Romito LM, et al. Long-term globus pallidus internus deep brain stimulation in pediatric non-degenerative dystonia: a cohort study and a meta-analysis. Mov Disord 2024;39(7):1131–1144. doi:10.1002/mds.29815. PMID 38646731. verified
- Elkaim LM, Alotaibi NM, Sigal A, et al. Deep brain stimulation for pediatric dystonia: a meta-analysis with individual participant data. Dev Med Child Neurol 2019;61(1):49–56. doi:10.1111/dmcn.14063. PMID 30320439. verified
- Koy A, Hellmich M, Pauls KA, et al. Effects of deep brain stimulation in dyskinetic cerebral palsy: a meta-analysis. Mov Disord 2013;28(5):647–654. doi:10.1002/mds.25339. PMID 23408442. verified
- Brüggemann N, Kühn A, Schneider SA, et al. Short- and long-term outcome of chronic pallidal neurostimulation in monogenic isolated dystonia. Neurology 2015;84(9):895–903. doi:10.1212/WNL.0000000000001312. PMID 25653290. verified
- Cif L, Demailly D, Lin JP, et al. KMT2B-related disorders: expansion of the phenotypic spectrum and long-term efficacy of deep brain stimulation. Brain 2020;143(11):3242–3261. doi:10.1093/brain/awaa304. PMID 33150406. verified
- Badhiwala JH, Karmur B, Elkaim LM, et al. Clinical phenotypes associated with outcomes following deep brain stimulation for childhood dystonia. J Neurosurg Pediatr 2019;24(4):442–450. doi:10.3171/2019.5.PEDS1973. PMID 31299640. verified
- Decraene B, Smeets S, Remans D, et al. Deep brain stimulation for GNAO1-associated dystonia: a systematic review and meta-analysis. Neuromodulation 2024;27(3):440–446. doi:10.1016/j.neurom.2023.10.187. PMID 37999699. verified
- De Vloo P, Lee DJ, Dallapiazza RF, et al. Deep brain stimulation for pantothenate kinase-associated neurodegeneration: a meta-analysis. Mov Disord 2019;34(2):264–273. doi:10.1002/mds.27563. PMID 30633810. verified
- Vidailhet M, Yelnik J, Lagrange C, et al. Bilateral pallidal deep brain stimulation for the treatment of patients with dystonia-choreoathetosis cerebral palsy: a prospective pilot study. Lancet Neurol 2009;8(8):709–717. doi:10.1016/S1474-4422(09)70151-670151-6). PMID 19576854. verified
- Koy A, Kühn AA, Huebl J, et al. Quality of life after deep brain stimulation of pediatric patients with dyskinetic cerebral palsy: a prospective, single-arm, multicenter study with a subsequent randomized double-blind crossover (STIM-CP). Mov Disord 2022;37(4):799–811. doi:10.1002/mds.28898. PMID 34967053. verified
- Koy A, Kühn AA, Schiller P, et al. Long-term follow-up of pediatric patients with dyskinetic cerebral palsy and deep brain stimulation. Mov Disord 2023;38(9):1736–1742. doi:10.1002/mds.29516. PMID 37358761. verified
- Barkey S, Ainaga L, Navarrete Muñoz EM, et al. Deep brain stimulation outcomes and management of childhood-onset dystonia and associated hyperkinetic movements disorders. Dev Med Child Neurol 2026 (online ahead of print). doi:10.1111/dmcn.70481. PMID 42658563. verified
- Vogt LM, Yan H, Santyr B, et al. Deep brain stimulation for refractory status dystonicus in children: multicenter case series and systematic review. Ann Neurol 2024;95(1):156–173. doi:10.1002/ana.26799. PMID 37714824. verified
- Vogt LM, Yang K, Tse G, et al. Recommendations for the management of initial and refractory pediatric status dystonicus. Mov Disord 2024;39(9):1435–1445. doi:10.1002/mds.29794. PMID 38619077. verified
- Balachandar A, Verhey LH, Mithani K, et al. Surgical complications of deep brain stimulation in children across targets and indications: multicenter analysis of the CHILD-DBS registry. Neurology 2025;105(9):e214201. doi:10.1212/WNL.0000000000214201. PMID 41071966. verified
- Starr PA, Turner RS, Rau G, et al. Microelectrode-guided implantation of deep brain stimulators into the globus pallidus internus for dystonia: techniques, electrode locations, and outcomes. Neurosurg Focus 2004;17(1):E4. doi:10.3171/foc.2004.17.1.4. PMID 15264773. verified
- Reich MM, Horn A, Lange F, et al. Probabilistic mapping of the antidystonic effect of pallidal neurostimulation: a multicentre imaging study. Brain 2019;142(5):1386–1398. doi:10.1093/brain/awz046. PMID 30851091. verified
- Cheung T, Noecker AM, Alterman RL, et al. Defining a therapeutic target for pallidal deep brain stimulation for dystonia. Ann Neurol 2014;76(1):22–30. doi:10.1002/ana.24187. PMID 24852850. verified
- Lumsden DE, Tambirajoo K, Hasegawa H, et al. Probabilistic mapping of deep brain stimulation in childhood dystonia. Parkinsonism Relat Disord 2022;105:103–110. doi:10.1016/j.parkreldis.2022.11.006. PMID 36403506. verified
- Huh R, Jang I. Accuracy and outcomes of KYMERO robot-guided deep brain stimulation for dystonia: retrospective cohort analysis. J Korean Neurosurg Soc 2026;69(4):616–629. doi:10.3340/jkns.2025.0212. PMID 41582458. Full text (PMC) verified
- Jin ST, Lee MK, Ghang JY, et al. Deep brain stimulation of the globus pallidus in a 7-year-old girl with DYT1 generalized dystonia. J Korean Neurosurg Soc 2012;52(3):261–263. doi:10.3340/jkns.2012.52.3.261. PMID 23115674. Full text (PMC) verified
- Vayssiere N, Hemm S, Cif L, et al. Comparison of atlas- and magnetic resonance imaging-based stereotactic targeting of the globus pallidus internus in the performance of deep brain stimulation for treatment of dystonia. J Neurosurg 2002;96(4):673–679. doi:10.3171/jns.2002.96.4.0673. PMID 11990806. verified
- Vasques X, Cif L, Hess O, et al. Prognostic value of globus pallidus internus volume in primary dystonia treated by deep brain stimulation. J Neurosurg 2009;110(2):220–228. doi:10.3171/2008.3.17433. PMID 19012480. verified
- Trenado C, Nikolov P, Slotty PJ, et al. Intraoperative DBS targeting of the globus pallidus internus by using motor evoked potentials. J Neurol Sci 2024;463:123141. doi:10.1016/j.jns.2024.123141. PMID 39043070. verified
- Starr PA, Markun LC, Larson PS, et al. Interventional MRI-guided deep brain stimulation in pediatric dystonia: first experience with the ClearPoint system. J Neurosurg Pediatr 2014;14(4):400–408. doi:10.3171/2014.6.PEDS13605. PMID 25084088. verified
- Sharma VD, Bezchlibnyk YB, Isbaine F, et al. Clinical outcomes of pallidal deep brain stimulation for dystonia implanted using intraoperative MRI. J Neurosurg 2020;133(5):1582–1594. doi:10.3171/2019.6.JNS19548. PMID 31604331. verified
- David R, Scala MR, Ellenbogen J, et al. Review of the targeting accuracy of frameless and frame-based robot-assisted deep brain stimulation electrode implantation in pediatric patients using the Neurolocate module. J Neurosurg Pediatr 2024;33(3):207–213. doi:10.3171/2023.10.PEDS23275. PMID 38134418. verified
- Alterman RL, Miravite J, Weisz D, et al. Sixty hertz pallidal deep brain stimulation for primary torsion dystonia. Neurology 2007;69(7):681–688. doi:10.1212/01.wnl.0000267430.95106.ff. PMID 17698790. verified
- Mulroy E, Vijiaratnam N, De Roquemaurel A, et al. A practical guide to troubleshooting pallidal deep brain stimulation issues in patients with dystonia. Parkinsonism Relat Disord 2021;87:142–154. doi:10.1016/j.parkreldis.2021.05.017. PMID 34074583. verified
- Ågren R, Bartek J, Johansson A, et al. Pulse width and implantable pulse generator longevity in pallidal deep brain stimulation for dystonia: a population-based comparative effectiveness study. Stereotact Funct Neurosurg 2020;98(5):331–336. doi:10.1159/000508794. PMID 32668433. verified
- Lange F, Guarin DL, Mosert S, et al. Bradykinesia induced by pallidal neurostimulation in dystonia: clinical risk factors and anatomical mapping. NPJ Parkinsons Dis 2025;11(1):308. doi:10.1038/s41531-025-01177-8. PMID 41131044. verified
- Jensen MA, Neimat JS, Kerezoudis P, et al. Principles of stereotactic surgery. Oper Neurosurg 2025;28(3):303–321. doi:10.1227/ons.0000000000001422. PMID 39627171. Full text (PMC) verified
- Mirzadeh Z, Chapple K, Lambert M, et al. Parkinson's disease outcomes after intraoperative CT-guided "asleep" deep brain stimulation in the globus pallidus internus. J Neurosurg 2016;124(4):902–907. doi:10.3171/2015.4.JNS1550. PMID 26452116. verified
- Chen T, Mirzadeh Z, Chapple KM, et al. Clinical outcomes following awake and asleep deep brain stimulation for Parkinson disease. J Neurosurg 2018;130(1):109–120. doi:10.3171/2017.8.JNS17883. PMID 29547091. verified
Verification (2026-11-02): each reference's authors, title, journal, volume, pages, DOI and PMID were checked on PubMed, and every figure cited was checked against the PubMed abstract. Full texts were not reviewed. Reference 6 and reference 11 include adults (reference 11 is adults only). The chart combines values from references 3, 5, 9 and 10, which differ in design and follow-up. "Bilateral GPi is the standard" reflects the target used in references 3, 11 and 15 (GPi in 68 of 77 status dystonicus cases); the posteroventral location is from references 11 and 15. The targeting section (references 18–33) was added on 2026-11-02. The indirect coordinates come from the full text of reference 22 (a series of patients with primary dystonia, ages not stated in the abstract) and the pediatric example from the full text of reference 23. References 19, 20, 24, 25, 26, 28, 30–33 are adult or mixed-age. The location of the optic tract beneath GPi and the internal capsule medial to it is standard anatomy, given without a citation. References 34–36 (Ponce FA is a coauthor of 34 and senior author of 35; 36 is from the same group) were added at Dr. Hauptman's request. The landmark and physiology statements come from the full text of reference 34 on PMC. References 35 and 36 are adult Parkinson disease series. Specific millimeter distances from the internal capsule and the dorsal border of the optic tract, as used by Ponce's group, could not be verified from accessible abstracts or full texts and are not given. The chart and the coronal schematic are original figures.